Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

CR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+G)

CR rate is defined as the percentage of participants achieving a best response of CR or CRi.

Time frame: Up to Week 32

CR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+I)

CR rate is defined as the percentage of participants achieving a best response of CR or CRi.

Time frame: Up to Week 56

Overall response rate (ORR) as Assessed by IRC for (V+G)

ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an IRC.

Time frame: Up to Week 32

ORR as Assessed by IRC (V+I)

ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an IRC.

Time frame: Up to Week 56

ORR as Assessed by Investigator for (V+G)

ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an investigator.

Time frame: Up to Week 32

ORR Assessed by Investigator + Ibrutinib (V+I)

ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an investigator.

Time frame: Up to Week 56

Progression-Free Survival (PFS) as Assessed by IRC for (V+G)

PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 32

PFS as Assessed by IRC for (V+I)

PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 56

PFS as Assessed by Investigator for (V+G)

PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 32

PFS as Assessed by Investigator for (V+I)

PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 56

Duration of response (DOR) as Assessed by IRC for (V+G)

DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 32

DOR as Assessed by IRC for (V+I)

DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 56

DOR as Assessed by Investigator for (V+G)

DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 32

DOR as Assessed by Investigator for (V+I)

DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 56

Overall Survival (OS) for (V+G)

OS is defined as the time from the date of the first dose of any study drug until death due to any cause.

Time frame: Up to Week 32

OS for (V+I)

OS is defined as the time from the date of the first dose of any study drug until death due to any cause.

Time frame: Up to Week 56

Time to progression (TTP) as Assessed by IRC for (V+G)

TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 32

TTP as Assessed by IRC for (V+I)

TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.

Time frame: Up to Week 56

TTP as Assessed by Investigator for (V+G)

TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 32

TTP as Assessed by Investigator for (V+I)

TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.

Time frame: Up to Week 56